DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update - Business update conference call and webcast on

DelMar Pharmaceuticals Announces Third

Quarter Fiscal Year 2016 Financial Results and Corporate Update

- Business update conference call

and webcast on May 19, 2016 at 5 PM EST -

British Columbia and MENLO PARK, Calif., May 13, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc.

(OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development

and commercialization of new cancer therapies, today announced its financial results for the quarter ending March 31, 2016, the

third quarter of the 2016 fiscal year. The Company also highlighted

recent corporate and clinical achievements and provided an overview of expected near-term milestones.

DelMar management will host a business

update conference call and live webcast for investors, analysts and other interested parties on Thursday May 19, 2016 at 5 pm EST.

RECENT CORPORATE HIGHLIGHTS

"Our data continues to demonstrate

VAL-083's unique cytotoxic anti-cancer mechanism which may provide new treatment opportunities for patients whose cancer

has failed or is unlikely to respond to currently available therapies. In particular, the data we have presented in our refractory

GBM clinical trial positions us to advance this program into registration-directed Phase III clinical trials and we look forward

to discussing our proposed trial design with the FDA," said Jeffrey Bacha, DelMar's chairman & CEO.

"Importantly, new funds raised

subsequent to quarter end enable us to fund current operations through 2017 and help position DelMar to qualify to list its common

stock on a senior exchange."

EXPECTED NEAR-TERM MILESTONES

CONFERENCE CALL DETAILS

DelMar plans to host a conference call

on Thursday, May 19, 2016, at 5 p.m. Eastern Time, to discuss quarterly results and provide a corporate update. For both "listen-only"

participants and those who wish to take part in the question and answer portion of the call, the telephone Dial-in Number is 800-895-1549

(toll free) with Conference ID DELMAR. A link to the webcast and slides will be available on the IR Calendar of the Investors section

of the Company's website at www.delmarpharma.com and will be archived for 30 days.

SUMMARY OF FINANCIAL RESULTS FOR

THE THIRD QUARTER OF FISCAL YEAR 2016 ENDED MARCH 31, 2016

For the three months ended March 31,

2016 the Company reported a net loss of $1,140,401, or a net loss per share of $0.03, compared to a net loss of $2,086,719, or

a net loss per share of $0.05 for the three months ended March 31, 2015, as restated.

For the nine months ended March 31,

2016 the Company reported a net loss of $5,408,479, or a net loss per share of $0.12, compared to a net loss of $4,223,087, or

a net loss per share of $0.11 for the nine months ended March 31, 2015, as restated.

The following represents selected financial

information as of March 31, 2016. The Company's financial information has been prepared in accordance with U.S. GAAP and

this selected information should be read in conjunction with DelMar's consolidated financial statements and Management's

Discussion and Analysis ("MD&A"), as filed.

DelMar's financial statements

as filed with the U.S. Securities Exchange Commission can be viewed on the company's website at: http://ir.delmarpharma.com/all-sec-filings.

Selected Balance Sheet Data

Selected Statement of Operations Data

For the Three Months Ended:

For the Nine Months Ended:

VAL-083 is a "first-in-class,"

small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute,

VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia

both as a single-agent and in combination with other treatments. VAL-083 is approved in China for the treatment of chronic myelogenous

leukemia (CML) and lung cancer, and has received orphan drug designation in Europe and the U.S. for the treatment of malignant

DelMar has demonstrated that VAL-083's

anti-tumor activity is unaffected by the expression of MGMT, a DNA repair enzyme that is implicated in chemotherapy resistance

and poor outcomes in GBM patients following standard front-line treatment with Temodar (temozolomide).

DelMar recently announced the completion

of enrollment in a Phase II clinical trial of VAL-083 in refractory GBM. Patients have been enrolled at five clinical centers in

the United States: Mayo Clinic (Rochester, MN); UCSF (San Francisco, CA) and three centers associated with the Sarah Cannon Cancer

Research Institute (Nashville, TN, Sarasota, FL and Denver, CO).

In the Phase I dose-escalation portion

of the study, VAL-083 was well tolerated at doses up to 40mg/m2 using a regimen of daily x 3 every 21 days. Adverse

events were typically mild to moderate; no treatment-related serious adverse events reported at doses up to 40 mg/m2.

Dose limiting toxicity (DLT) defined by thrombocytopenia (low platelet counts) was observed in two of six (33%) of patients at

50 mg/m2. Generally, DLT-related symptoms resolved rapidly and spontaneously without concomitant treatment, although

one patient who presented with hemorrhoids received a platelet transfusion as a precautionary measure.

Sub-group analysis of data from the

Phase I dose-escalation portion of the study suggested a dose-dependent and clinically meaningful survival benefit following treatment

with VAL-083 in GBM patients whose tumors had progressed following standard treatment with temozolomide, radiotherapy, bevacizumab

and a range of salvage therapies.

Patients in a low dose ( 5mg/m2)

sub-group had a median survival of approximately five (5) months versus median survival of approximately nine (9) months for patients

in the therapeutic dose (30mg/m2 & 40mg/m2) sub-group following initiation of VAL-083 treatment. DelMar

reported increased survival at 6, 9 and 12 months following initiation of treatment with VAL-083 in the therapeutic dose sub-group

compared to the low dose sub-group.

Further details can be found at http://www.delmarpharma.com/scientific-publications.html.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded

to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern

targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the

U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer

Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical

and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could

provide improved treatment options for patients.

For further information, please visit

http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Connect with

the Company on Twitter, LinkedIn, Facebook, and Google+.

Safe Harbor Statement

Any statements contained in this

press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private

Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but

are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from

current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market

and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability

of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical

studies and future product commercialization; and, the Company's business, research, product development, regulatory approval,

marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings

with the SEC, including, our current reports on Form 8-K.